Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026)
Xilio Therapeutics (XLO) posted EBITDA Margin of 111.57% for Q1 2026, down 29.01% sequentially from 86.48% in Q4 2025, and up 36116.0% YoY from N/an in Q1 2025.
Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2026) Analysis & Trends
Xilio Therapeutics has reported EBITDA Margin for 3 years, with the latest figure at 111.57% in Q1 2026.
- Quarterly EBITDA Margin rose 36116.0% year-over-year to 111.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78.98% (up 53506.0% YoY) and the FY2025 annual result came in at 95.92%, up 85903.0% from the prior year.
- EBITDA Margin fell to 111.57% in Q1 2026 per XLO's latest filing, from 86.48% in the prior quarter.
- Over five years, EBITDA Margin peaked at 10.12% in Q3 2025 and troughed at 790.55% in Q4 2024.
- A 3-year average of 365.67% and a median of 325.22% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin soared 70406 bps in 2025, then soared 36116 bps in 2026.
- Over 3 years, EBITDA Margin stood at 790.55% in 2024, then soared by 89 bps to 86.48% in 2025, then decreased by 29 bps to 111.57% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 111.57%, 86.48%, and 10.12% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 19.75% |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -18.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.68% |
| Mar 31, 2026 | -111.57% |
| Dec 31, 2025 | -86.48% |
| Sep 30, 2025 | -10.12% |
| Jun 30, 2025 | -177.71% |
| Mar 31, 2025 | -472.73% |
| Dec 31, 2024 | -790.55% |
| Sep 30, 2024 | -652.32% |
| Jun 30, 2024 | -623.84% |